Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax submits hepatitis B vaccine BLA to FDA
In Phase III trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. Dynavax president and chief medical officer Tyler Martin said the final
In Phase III trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. Dynavax president and chief medical officer Tyler Martin said the final
Under the terms of the agreement, Teva may launch a generic epinephrine auto-injector covered by its ANDA on 22 June 2015 or earlier under certain circumstances, subject to
The approval is based on the results of the randomized, double-blind, placebo controlled Phase III study called PAzopanib ExpLorEd in sofT Tissue sarcoma (PALETTE). GSK Oncology president Paolo
The approval was based on the Phase III EXamining everolimus In a Study of TSC trial, which found that 42% of patients on everolimus experienced an angiomyolipoma response
With the completion of the acquisition, ZOLL Medical, a US-based manufacturer of medical devices, has become a wholly owned consolidated subsidiary of Asahi. ZOLL will continue to be
The product is available in a metered pump dispenser and is delivered transdermally, resulting in a low level of side effects such as dry mouth and constipation, common
Anatabloc is a dietary supplement that contains active dietary ingredients, anatabine citrate and vitamins A and D3, to provide anti-inflammatory support. The study, entitled "A Three Month, Single-Site
ConfirmMDx is a laboratory-developed test (LDT), which assists urologists with identifying men who may safely forego unnecessary repeat biopsies. The prostate cancer assay can also identify an epigenetic
Under the drug discovery program, Vernalis will receive a payment of €0.5m from Servier on achieving the target. In addition, Vernalis will receive fees and a share in
Frontage will commence work on the analysis, formulation and validation of the various processes and procedures for manufacturing AHRO-001 in advance of the upcoming Phase I human clinical